Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Rocket Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -245.60 | -221.86 | -169.07 | -139.70 | -77.27 |
Depreciation/Amortization & Depletion | 7.10 | 6.40 | 5.37 | 1.15 | 0.43 |
Net Change from Assets/Liabilities | 13.46 | 6.08 | -3.39 | 15.03 | -3.73 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 30.12 | 31.25 | 45.92 | 48.89 | 15.91 |
Net Cash From Operating Activities | -194.92 | -178.14 | -121.16 | -74.64 | -64.66 |
Property & Equipment | -16.44 | -8.36 | -7.62 | -20.61 | -23.27 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 42.73 | 0.00 | 0.00 | 0.00 |
Investments | -81.59 | -103.43 | 26.57 | -67.53 | -15.74 |
Other Investing Activities | -0.04 | -0.26 | -0.10 | -8.45 | 0.00 |
Net Cash from Investing Activities | -98.07 | -69.33 | 18.85 | -96.59 | -39.01 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 208.40 | 155.29 | 37.68 | 283.84 | 178.14 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.85 | -0.34 |
Net Cash from Financing Activities | 208.40 | 155.29 | 37.68 | 282.99 | 177.79 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -84.58 | -92.18 | -64.63 | 111.76 | 74.12 |
Cash at Beginning of Period | 141.86 | 234.04 | 298.67 | 186.91 | 112.79 |
Cash at End of Period | 57.28 | 141.86 | 234.04 | 298.67 | 186.91 |
Diluted Net EPS | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 |
Fiscal Year End for Rocket Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -245.60 | -185.94 | -124.04 | -58.34 |
Depreciation/Amortization & Depletion | NA | 7.10 | -1.91 | -1.43 | 1.67 |
Net Change from Assets/Liabilities | NA | 13.46 | -8.07 | -2.13 | -7.47 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 30.12 | 30.34 | 19.16 | 6.57 |
Net Cash From Operating Activities | NA | -194.92 | -165.58 | -108.43 | -57.56 |
Property & Equipment | NA | -16.44 | -11.79 | -7.13 | -3.02 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | -0.01 |
Investments | NA | -81.59 | 54.56 | 1.66 | -33.70 |
Other Investing Activities | NA | -0.04 | -0.04 | -0.04 | 0.00 |
Net Cash from Investing Activities | NA | -98.07 | 42.74 | -5.52 | -36.72 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 208.40 | 208.01 | 18.53 | 18.34 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 208.40 | 208.01 | 18.53 | 18.34 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -84.58 | 85.17 | -95.42 | -75.94 |
Cash at Beginning of Period | NA | 141.86 | 141.86 | 141.86 | 141.86 |
Cash at End of Period | NA | 57.28 | 227.03 | 46.44 | 65.92 |
Diluted Net EPS | NA | -0.62 | -0.75 | -0.82 | -0.73 |